Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

• Status: Completed
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective is to establish the impact of current disease modifying therapies (DMTs) and associated support services on Patient Reported Experience Measures and Patient Reported Outcomes in relation to the treatment and management of Relapsing Multiple Sclerosis in the United Kingdom (UK).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck KGaA; Merck KGaA, Darmstadt, Germany
• Collaborator: Merck Serono Limited, UK
• Treatments: Interferon beta-1a

Criteria

Inclusion Criteria:

• Relapsing Multiple Sclerosis patients aged 18 years or over.

• Naive to previous DMT therapy and not yet started treatment with a disease modifying therapy.

Exclusion Criteria:

• Participating in an MS-related clinical trial.

• Unwilling to provide electronic online consent.

• Any disability that may impair them from being able to complete the online questionnaire.

• Do not have regular access to the Internet.

• Unable to complete the baseline questionnaire before they receive their first DMT injection.